Daré Bioscience to Participate in Two Upcoming Conferences
September 15 2022 - 8:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced that Sabrina Martucci Johnson, the
company’s President and CEO, will participate in two upcoming
conferences.
Informa Connect Women’s Healthcare Access
& Innovation Digital Conference |
September 21, 2022, 1:15-1:45 PM Eastern Time |
|
Presentation:
Novel Approaches to Non-Hormonal Female Contraception |
|
Sabrina
Martucci Johnson, President and CEO, Daré Bioscience |
To learn more about the event and register,
visit: https://informaconnect.com/womens-healthcare-access-innovation/
Longwood Healthcare Leaders Fall
Webconference |
September 22, 2022, 12:15-12:45 PM Eastern
Time |
|
Panel:
Innovative Partnerships |
|
Brian McVeigh, CEO, Code
Bio (moderator) |
|
Ken Drazan, Chairman and CEO, Arsenal Biosciences |
|
Sabrina Martucci Johnson, President and CEO, Daré
Bioscience |
|
Jason Kelly, CEO, Ginkgo Bioworks |
|
Matthias Müllenbeck, VP, Head, Global BD & Alliance
Management, EMD Serono |
|
Jennifer Petter, PhD, Chief Innovation Officer, Arrakis
Therapeutics |
Longwood Healthcare Leaders meetings are by invitation only. To
learn more about the event, view the agenda, and request an
invitation, visit www.longwoodhealthcareleaders.com.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company
committed to advancing innovative products for women’s health. The
company’s mission is to identify, develop and bring to market a
diverse portfolio of differentiated therapies that prioritize
women's health and well-being, expand treatment options, and
improve outcomes, primarily in the areas of contraception,
fertility, and vaginal and sexual health.
Daré’s first FDA-approved product, XACIATOTM
(clindamycin phosphate) vaginal gel, 2% is a lincosamide
antibacterial indicated for the treatment of bacterial vaginosis in
female patients 12 years of age and older, which is under a global
license agreement with Organon. XACIATO is a clear, colorless,
viscous gel, to be administered once intravaginally as a single
dose. Daré’s portfolio also includes potential first-in-category
candidates in clinical development: Ovaprene®, a novel,
hormone-free monthly contraceptive whose U.S. commercial
rights are under a license agreement with Bayer; Sildenafil Cream,
3.6%, a novel cream formulation of sildenafil to treat female
sexual arousal disorder utilizing the active ingredient in Viagra®;
and DARE-HRT1, a combination bio-identical estradiol and
progesterone intravaginal ring for hormone therapy following
menopause. To learn more about XACIATO, Daré’s full portfolio of
women’s health product candidates, and Daré’s mission to deliver
differentiated therapies for women, please
visit www.darebioscience.com.
Daré may announce material information about its
finances, product and product candidates, clinical trials and other
matters using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company, and may also use
social media to communicate important information about the
company, its finances, product and product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and
@DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted in
the Investors section of Daré’s website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Lee Roth Burns
McClellanlroth@burnsmc.com212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:Jake RobisonEvoke
Canale jake.robison@evokegroup.com 619.849.5383
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2023 to Jul 2024